Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Net Margin (2021 - 2025)

Verrica Pharmaceuticals has reported Net Margin over the past 5 years, most recently at 163.02% for Q4 2025.

  • Quarterly results put Net Margin at 163.02% for Q4 2025, up 377710.0% from a year ago — trailing twelve months through Dec 2025 was 51.72% (up 61254.0% YoY), and the annual figure for FY2025 was 53.4%, up 92352.0%.
  • Net Margin for Q4 2025 was 163.02% at Verrica Pharmaceuticals, down from 2.15% in the prior quarter.
  • Over the last five years, Net Margin for VRCA hit a ceiling of 1.61% in Q2 2025 and a floor of 17808.11% in Q1 2023.
  • Median Net Margin over the past 5 years was 850.26% (2023), compared with a mean of 2818.46%.
  • Biggest five-year swings in Net Margin: tumbled -1584291bps in 2023 and later surged 1727701bps in 2024.
  • Verrica Pharmaceuticals' Net Margin stood at 7.8% in 2021, then tumbled by -111608bps to 8713.24% in 2022, then surged by 86bps to 1239.89% in 2023, then tumbled by -218bps to 3940.12% in 2024, then soared by 96bps to 163.02% in 2025.
  • The last three reported values for Net Margin were 163.02% (Q4 2025), 2.15% (Q3 2025), and 1.61% (Q2 2025) per Business Quant data.